Table 3 Serum levels of cancer biomarkers at admission and after neoadjuvant chemotherapy (NACT) in patients with breast cancer.
From: Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer
Biomarkers | At admission (n = 134) | After NACT (n = 134) | Therapeutic response | |||
|---|---|---|---|---|---|---|
CR | PR | SD | PD | |||
CA153, U/mL | 26.13 ± 3.15 | 25.11 ± 2.15 | 25.89 ± 2.05 | 25.01 ± 1.75 | 25.34 ± 2.05 | 26.21 ± 2.45 |
CK19, U/mL | 2.79 ± 0.94 | 2.69 ± 0.97 | 2.56 ± 0.87 | 2.72 ± 0.87 | 2.39 ± 0.67 | 2.79 ± 0.99 |
CEA, ng/mL | 4.43 ± 1.25 | 4.34 ± 1.21 | 4.24 ± 1.11 | 4.32 ± 1.29 | 4.54 ± 1.31 | 4.17 ± 1.26 |
HMGB1, ng/mL | 5.77 ± 1.95 | 2.18 ± 1.15*** | 0.78 ± 0.25*** | 1.08 ± 1.05*** | 3.22 ± 1.75* | 5.98 ± 2.15 |
E-cadherin, ng/mL | 1878.41 ± 57.31 | 842.61 ± 17.31*** | 242.11 ± 11.21*** | 472.67 ± 12.41*** | 1242.21 ± 27.51* | 1962.61 ± 62.41 |
